Omnicell, Inc. (NASDAQ:OMCL) has been given an average recommendation of “Buy” by the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $47.00.

Several analysts have recently commented on OMCL shares. Piper Jaffray Companies lowered shares of Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price target on the stock. in a research report on Friday, April 21st. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $53.00 price target (up previously from $43.00) on shares of Omnicell in a research report on Tuesday, April 25th. CIBC lifted their price target on shares of Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, April 26th. TheStreet lowered shares of Omnicell from a “b-” rating to a “c+” rating in a research report on Thursday, May 4th. Finally, Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th.

COPYRIGHT VIOLATION WARNING: “Omnicell, Inc. (NASDAQ:OMCL) Given Average Rating of “Buy” by Brokerages” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/14/omnicell-inc-nasdaqomcl-given-average-rating-of-buy-by-brokerages.html.

In other Omnicell news, Chairman Randall A. Lipps sold 18,200 shares of the business’s stock in a transaction that occurred on Tuesday, April 25th. The stock was sold at an average price of $41.00, for a total value of $746,200.00. Following the sale, the chairman now owns 208,982 shares of the company’s stock, valued at $8,568,262. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Randall A. Lipps sold 31,527 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $42.87, for a total value of $1,351,562.49. Following the completion of the sale, the chairman now directly owns 196,551 shares in the company, valued at approximately $8,426,141.37. The disclosure for this sale can be found here. In the last three months, insiders sold 101,000 shares of company stock worth $4,221,001. 3.75% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Omnicell during the fourth quarter worth about $1,628,000. State Street Corp raised its stake in shares of Omnicell by 8.1% in the fourth quarter. State Street Corp now owns 802,579 shares of the company’s stock worth $27,210,000 after buying an additional 60,375 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Omnicell during the fourth quarter worth about $788,000. Guggenheim Capital LLC raised its stake in shares of Omnicell by 75.4% in the fourth quarter. Guggenheim Capital LLC now owns 48,053 shares of the company’s stock worth $1,628,000 after buying an additional 20,663 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Omnicell by 26.6% in the fourth quarter. AQR Capital Management LLC now owns 24,935 shares of the company’s stock worth $845,000 after buying an additional 5,236 shares during the last quarter. 96.35% of the stock is currently owned by institutional investors.

Shares of Omnicell (OMCL) traded up 0.70% during midday trading on Friday, reaching $43.00. The company’s stock had a trading volume of 28,023 shares. The stock’s 50 day moving average price is $42.12 and its 200 day moving average price is $38.65. The firm’s market cap is $1.60 billion. Omnicell has a one year low of $30.35 and a one year high of $44.60.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, May 4th. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.36. The firm had revenue of $150.90 million for the quarter, compared to analyst estimates of $152.63 million. Omnicell had a negative net margin of 1.45% and a positive return on equity of 2.66%. The business’s revenue for the quarter was down 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.35 EPS. Analysts predict that Omnicell will post $1.28 earnings per share for the current year.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.